AI Article Synopsis
- Sandostatin was administered to 30 patients with destructive pancreatitis at doses between 200-600 micrograms per day, effectively reducing pancreatic enzyme toxin production.
- Despite its benefits, Sandostatin did not stop the progression of necrotic areas in the pancreas or surrounding fat.
- Treatment duration should be limited to 5-7 days; if no improvement is seen, surgery may be necessary, and traditional medications should not be completely replaced by Sandostatin.
Article Abstract
Sandostatin has been used in combined treatment of 30 patients with destructive pancreatitis in a dose 200-600 micrograms/day subcutaneously. The drug significantly depressed production of enzyme toxins in the pancreas but failed to prevent widening of necrotic zones and progression of the process in the retroperitoneal fat. The duration of sandostatin treatment should not be longer than 5-7 days. If no response is achieved for this time, surgical treatment is indicated. It is not reasonable to reject conventional drugs used in acute destructive pancreatitis for sandostatin monotherapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
destructive pancreatitis
8
[sandostatin treatment
4
treatment destructive
4
destructive pancreatitis]
4
pancreatitis] sandostatin
4
sandostatin combined
4
combined treatment
4
treatment patients
4
patients destructive
4
pancreatitis dose
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!